There are 3161 resources available
1349P - A prospective study on clinicians’ attitudes and survival outcomes for patients with NSCLC and poor performance status in the immunotherapy era: PICASO study (GOIRC-04-2020)
Presenter: Francesco Facchinetti
Session: Poster session 05
1350P - Phase I/II trial shows promising efficacy of nadunolimab in combination with platinum doublet as second-line therapy in patients with NSCLC
Presenter: Astrid Paulus
Session: Poster session 05
1351P - Heme-oxygenase-1 (HO-1) as a potential biomarker for ICIs in patients with advanced lung cancer
Presenter: Federica Biello
Session: Poster session 05
1352P - Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
Presenter: Marco Russano
Session: Poster session 06
1353P - Efficacy and safety of docetaxel in combination with nintedanib or ramucirumab following immune checkpoint-Inhibitor treatment in patients with non-small cell lung cancer
Presenter: Konstantinos Ferentinos
Session: Poster session 06
1354P - Retrospective audit to determine the effect of antibiotic therapy on immune checkpoint inhibitor efficacy in stage IV NSCLC
Presenter: Deevyashali Parekh
Session: Poster session 06
1356P - Transcriptomic inflammatory profiling of non-small cell lung cancer: Insights from a 7-gene expression analysis
Presenter: Elba Marin
Session: Poster session 06
1357P - Multicenter phase II study of cisplatin and gemcitabine plus necitumumab in patients with unresectable, advanced lung squamous cell carcinoma who have progressed on or after initial treatment with immune checkpoint inhibitors plus platinum-based chemotherapy: WJOG14120L NESSIE study
Presenter: Hiroshige Yoshioka
Session: Poster session 06
1358P - Plinabulin/docetaxel versus docetaxel in survival benefits of 2L/3L EGFR wild-type NSCLC after platinum regimens (DUBLIN-3): A randomized phase III trial
Presenter: Trevor Feinstein
Session: Poster session 06